Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 24, 2018

Interim Analysis of the OBOE (Ocrelizumab Biomarker Outcome Evaluation) Study in Multiple Sclerosis (MS) (S24.002)

Amit Bar-Or, Jeffrey Gelfand, Damian Fiore, Christopher Harp, Xiaoye Ma, Ann Herman, Bruno Musch, Hanzhe Zheng, Anne Cross
First published April 9, 2018,
Amit Bar-Or
1University of Pennsylvania Philadelphia PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Gelfand
2University of California, San Francisco San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Damian Fiore
3Genentech, Inc. South San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Harp
3Genentech, Inc. South San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoye Ma
4Genentech South San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ann Herman
3Genentech, Inc. South San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno Musch
3Genentech, Inc. South San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hanzhe Zheng
3Genentech, Inc. South San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Cross
5Washington University School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Interim Analysis of the OBOE (Ocrelizumab Biomarker Outcome Evaluation) Study in Multiple Sclerosis (MS) (S24.002)
Amit Bar-Or, Jeffrey Gelfand, Damian Fiore, Christopher Harp, Xiaoye Ma, Ann Herman, Bruno Musch, Hanzhe Zheng, Anne Cross
Neurology Apr 2018, 90 (15 Supplement) S24.002;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To provide interim analysis of the ocrelizumab cerebrospinal fluid (CSF) and blood biomarker study (OBOE, NCT02688985) in multiple sclerosis (MS).

Background: CSF biomarkers, including neurofilament light chain (NfL) and lymphocyte numbers, are potential indicators of central nervous system status and may improve understanding of MS disease pathways and therapeutic mechanisms of action.

Design/Methods Patients with relapsing (RMS) or primary progressive MS receive ocrelizumab 600 mg every 24 weeks. CSF is obtained by lumbar puncture (LP) before and at 12, 24, or 52 weeks after ocrelizumab treatment; an RMS control arm receives 2 LPs 12 weeks apart before starting ocrelizumab. Biomarkers are reported in RMS patients with pre-ocrelizumab and 12-week (Arm 1) and 24-week (Arm 2) post-ocrelizumab CSF available for interim analysis as of a June 1, 2017 clinical cutoff date (n=40). Safety data for all enrolled patients as of the cutoff is presented (n=82).

Results: CSF samples from Weeks 12 and 24 post-ocrelizumab treatment exhibited reductions in median concentration of NfL (−24%, −47%); median number of CD19+ B cells (−86%, −82%) and median number of CD3+ T cells (−60%, −67%). Ocrelizumab was generally well tolerated, consistent with safety in the Phase 3 studies. Infusion-related reactions (44%) and 1 serious adverse event (seizure) were reported. No serious infections, malignancies or deaths were reported.

Conclusions: NfL decreased at 12 weeks, appeared to decrease further at 24 weeks, and correlated with CSF B and T cell numbers, suggesting continued reduction in axonal injury with ocrelizumab treatment, and that levels of CSF inflammatory cells may predict neuronal injury. A single dose of ocrelizumab reduced but did not completely deplete CSF B cells while also reducing CSF T cells, indicating B cells may function in T-cell antigen presentation, recruitment and/or maintenance in the CSF. The trial is continuing, with final results expected in early 2019.

Study Supported by:

Sponsored by Genentech, Inc.

Disclosure: Dr. Bar-Or has nothing to disclose. Dr. Gelfand has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with . Dr. Fiore has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genentech. Dr. Harp has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genentech. Dr. Zheng has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Compensation from Genentech and stock in F. Hoffmann-La Roche Ltd as Genentech employee. Dr. Herman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genentech. Dr. Musch has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genentech. Dr. Cross has received personal compensation for activities with AbbVie, BAYER, Biogen, EMD Serono, Genentech/Roche, Genzyme/Sanofi, Novartis, and Teva. Dr. Cross has received research support for Genentech/ Roche.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (9)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise